Dementia Unit, University Hospital Virgen de la Arrixaca, Murcia, Spain.
Alzheimers Dement. 2011 Jul;7(4):e124-9. doi: 10.1016/j.jalz.2011.05.2412.
Complement receptor 1 gene polymorphism rs3818361 was recently shown to increase the risk of Alzheimer's disease (AD). We performed an independent replication study of this genetic variant in 2,470 individuals from Spain. By applying an allelic model, we observed a trend toward an association between this marker and late-onset AD susceptibility in our case-control study (odds ratio = 1.114, 95% confidence interval: 0.958-1.296, P = .16). Meta-analysis of available studies (n = 31,771 individuals), including previous studies and public genome-wide association study resources (Alzheimer's Disease Neuroimaging Initiative, Translational Genomics Research Institute, and Multi-site Collaborative Study for Genotype-Phenotype Associations in Alzheimer's Disease), strongly supports the effect of rs3818361 (odds ratio = 1.180, 95% confidence interval: 1.113-1.252, P < 2.99E-8) and suggests the existence of between-study heterogeneity (P < .05). We concluded that the complement receptor 1 gene may contribute to AD risk, although its effect size could be smaller than previously estimated.
补体受体 1 基因多态性 rs3818361 最近被证明会增加阿尔茨海默病(AD)的风险。我们在来自西班牙的 2470 个人中进行了这项遗传变异的独立复制研究。通过应用等位基因模型,我们在病例对照研究中观察到该标记物与晚发性 AD 易感性之间存在关联的趋势(比值比=1.114,95%置信区间:0.958-1.296,P=0.16)。对现有研究(n=31771 人)的荟萃分析,包括之前的研究和公共全基因组关联研究资源(阿尔茨海默病神经影像学倡议、转化基因组学研究所以及阿尔茨海默病基因型-表型关联的多地点合作研究),强烈支持 rs3818361 的作用(比值比=1.180,95%置信区间:1.113-1.252,P<2.99E-8),并表明存在研究间异质性(P<0.05)。我们得出结论,补体受体 1 基因可能导致 AD 风险增加,尽管其效应大小可能小于先前估计。